| TOTAL | $22M |
| VENTURE FUNDING TOTAL | $22M |
| Series B, 6/07 The Vertical Group Integra Ventures Novartis Venture Fund Westfield Capital Management | $10.7M |
| Venture Round, 3/12 | $11.3M |
Tepha is a medical device firm pursuing the development and commercialization of innovative products based on the Company’s proprietary biomaterial technology. The technology provides a new class of absorbable biomaterials, known as polyhydroxyalkanoates (a.k.a. PHAs), which may be tailored to meet unmet needs for medical devices in multiple fields. Tepha’s novel, biosynthetically produced materials offer superior performance in flexibility, elasticity, and biocompatibility; and, for its fiber-based products, excellent tensile strength and strength retention.
